Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223635 · ClinicalTrials.gov registry record · Early Phase 1
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
A Early Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT04223635 is a Early Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 16 participants.
The verdict
NCT04223635, a Early Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The pharmacokinetics of a single dose of pexidartinib was investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
Interventions
- DRUG Pexidartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-01-07 |
| Est. Completion | 2020-10-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04223635
The ClinicalTrials.gov registry entry for NCT04223635 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pexidartinib is the first listed.
NCT04223635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04223635 about?
NCT04223635 is a clinical study titled "Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants". The pharmacokinetics of a single dose of pexidartinib was investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.
What is the current status of trial NCT04223635?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2020-01-07. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT04223635?
The interventions under investigation include: Pexidartinib (DRUG).
Who is sponsoring clinical trial NCT04223635?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.